Every 10-Q that Prelude Therapeutics Incorporated (PRLD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PRLD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRLD filings page.
Prelude Therapeutics Incorporated reported for the quarter and six months ended June 30, 2026 as a clinical-stage precision oncology company with no product sales but new collaboration revenue. Revenue was $5.7 million for the quarter and $10.3 million for the first half of 2026, all from its exclusive option agreement with Incyte on the JAK2 V617F program.
Operating expenses declined as the company paused its SMARCA2 degrader trials and reduced headcount. Research and development expense fell to $16.1 million for the quarter and $29.7 million year-to-date, while general and administrative expense also decreased. Net loss narrowed to $13.9 million for the quarter and $24.3 million for the first half.
Liquidity was strengthened by an April equity offering and pre-funded warrants that generated approximately $85.4 million in net proceeds. Cash, cash equivalents, restricted cash, and marketable securities totaled $155.2 million as of June 30, 2026, which management believes will fund operations and capital needs for at least twelve months. The pipeline is led by a mutant-selective JAK2 V617F inhibitor in Phase 1 and a KAT6A degrader expected to enter Phase 1 after IND clearance.
Prelude Therapeutics reported a significantly smaller net loss of $10.4 million for the quarter ended March 31, 2026, compared with $32.1 million a year earlier. The improvement was driven by recognizing $4.6 million of collaboration revenue from its Exclusive Option Agreement with Incyte and sharply lower research and development spending.
R&D expense fell to $13.6 million from $28.8 million, mainly after pausing SMARCA2 clinical programs and reducing internal costs, while general and administrative expense edged down to $5.2 million. Prelude ended the quarter with $84.8 million in cash, cash equivalents, restricted cash and marketable securities, and subsequently raised an estimated $85.5 million of net proceeds in an April equity and pre‑funded warrant offering, extending its liquidity.
Prelude Therapeutics (PRLD) filed its Q3 2025 10‑Q, reporting revenue of $6.5 million from an amended AbCellera collaboration, total operating expenses of $26.9 million, and a net loss of $19.7 million ($0.26 per share). Cash, cash equivalents, restricted cash and marketable securities were $58.2 million as of September 30, 2025.
Subsequent to quarter‑end, the company received $6 million from an expanded AbCellera agreement and $60 million in capital from Incyte (an initial $35 million in cash plus a $25 million equity investment at $4.00 per share for 6,250,000 non‑voting shares). As of November 10, 2025, 62,865,270 voting and non‑voting common shares were outstanding. Based on preliminary estimates, these funds and existing balances could extend cash runway into 2027; however, the company states that substantial doubt exists about its ability to continue as a going concern.
Management announced a pause of the SMARCA2 degrader program, an ~11% workforce reduction with $0.5 million in one‑time costs, and noted regained compliance with Nasdaq’s $1.00 minimum bid price requirement. Year‑to‑date operating cash use was $79.4 million, partially offset by $113.8 million provided by investing activities from marketable securities maturities.
Prelude Therapeutics reported continued operating losses while advancing multiple oncology programs and managing liquidity constraints. For the six months ended June 30, 2025, the company recorded a $63.3 million net loss and had an accumulated deficit of $646.9 million. At June 30, 2025, cash, cash equivalents, restricted cash and marketable securities totaled $77.3 million, but management states these funds are insufficient to cover at least the next twelve months absent additional financing, and substantial doubt exists about the company’s ability to continue as a going concern.
Operationally, R&D and G&A decreased year-over-year to $54.6 million and $12.2 million for the six months, respectively, as clinical expenses and stock-based compensation moderated. Key program milestones include ongoing Phase 1/2 activity for SMARCA2 degraders (PRT3789 and oral PRT7732) and collaborations with AbCellera and Merck. The company also received a Nasdaq bid price deficiency notice with an initial compliance period through September 23, 2025, and maintains a $400 million shelf registration and a $75 million sales agreement capacity that could support future financing.